T

    Tandem Diabetes Care Inc (TNDM)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $22.01
    +0.58 (+2.71%)

    Market Cap: $1.49B

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    55%(22/40)
    Avg Surprise
    -42.52%
    Streak
    4 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.24
    Range$-0.36 - $-0.16
    19 analysts
    EPS RevisionsNo revisions (7d)
    0
    3
    30d
    EPS Estimate Drift
    90d ago$-0.19+22.7%
    60d ago$-0.20+17.1%
    30d ago$-0.19+21.8%
    7d ago$-0.24+0.4%
    Current$-0.24
    Revenue Consensus
    $266M
    Range$263M - $274M
    22 analysts
    Dec 31, 2026
    EPS Consensus$0.34
    Range$0.09 - $0.55
    20 analysts
    Revenue Consensus
    $311M
    Range$302M - $320M
    24 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.34---
    Sep 26EST
    		-$-0.24---
    Jun 26
    		$-0.31$-0.34+8.82%Beat+35.4%
    Mar 26
    		$-0.30$-0.44+31.82%Beat+55.2%
    Dec 25
    		$-0.01N/A+88.89%Beat+97.7%
    Sep 25
    		$-0.31$-0.34+8.82%Beat+13.9%
    Jun 25
    		$-0.48$-0.40-20.00%Miss+0.0%
    Mar 25
    		$-0.67$-0.61-9.84%Miss-4.7%
    Dec 24
    		$-0.44$-0.24-84.81%Miss-61.3%
    Sep 24
    		$-0.36$-0.41+12.20%Beat+5.3%
    Jun 24
    		$-0.48$-0.53+9.43%Beat-60.0%
    Mar 24
    		$-0.64$-0.76+15.79%Beat-1.6%
    Dec 23
    		$-0.27$-0.25-8.00%Miss-8.0%
    Sep 23
    		$-0.38$-0.36-5.56%Miss-40.7%
    Jun 23
    		$-0.30$-0.49+38.78%Beat-30.4%
    Mar 23
    		$-0.63$-0.53-18.87%Miss-173.9%
    Dec 22
    		$-0.25$-0.06-316.67%Miss-256.3%
    Sep 22
    		$-0.27$-0.05-440.00%Miss-400.0%
    Jun 22
    		$-0.23$0.02-1250.00%Miss-483.3%
    Mar 22
    		$-0.23$-0.07-228.57%Miss-187.5%
    Dec 21
    		$0.16$0.21-23.81%Miss-27.3%
    Sep 21
    		$0.09$0.06+50.00%Beat+160.0%
    Jun 21
    		$0.06$-0.08+175.00%Beat+113.3%
    Mar 21
    		$-0.08$-0.15+46.67%Beat+68.0%
    Dec 20
    		$0.22$0.12+83.33%Beat+450.0%
    Sep 20
    		$-0.15$-0.12-25.00%Miss-66.7%
    Jun 20
    		$-0.45$-0.25-80.00%Miss-1400.0%
    Mar 20
    		$-0.25$-0.18-38.89%Miss+37.5%
    Dec 19
    		$0.04$-0.05+180.00%Beat+100.0%
    Sep 19
    		$-0.09N/A+59.09%Beat+70.0%
    Jun 19
    		$-0.03N/A+89.66%Beat+90.9%
    Mar 19
    		$-0.40$-0.29-37.93%Miss+61.2%
    Dec 18
    		$0.02N/A+110.00%Beat+101.6%
    Sep 18
    		$-0.30$-0.31+3.23%Beat+91.6%
    Jun 18
    		$-0.33$-0.33+0.00%Beat+92.5%
    Mar 18
    		$-1.03$-0.62-66.13%Miss+86.3%
    Dec 17
    		$-1.22$-1.30+6.15%Beat+78.0%
    Sep 17
    		$-3.59$-3.74+4.01%Beat+63.0%
    Jun 17
    		$-4.40$-4.79+8.14%Beat-
    Mar 17
    		$-7.50$-6.11-22.75%Miss-
    Dec 16
    		$-5.55$-6.49+14.48%Beat-
    Sep 16
    		$-9.70$-5.77-68.11%Miss-

    Key Metrics

    Valuation
    P/E Ratio-23.67EV/EBITDA345.75x
    Price/FCF-57.06xFCF Yield-1.75%
    Profitability
    Profit Margin-6.08%Operating Margin-5.42%
    ROE-48.00%ROIC-6.25%
    Financial Health
    Debt/Equity4.62xInterest Coverage-5.21x
    Current Ratio3.18xQuick Ratio2.65x
    Trading Statistics
    Beta1.54Avg Volume2.09M
    52-Week High$29.6552-Week Low$11.46

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$22.21
    SMA 20$22.04
    SMA 50$18.69
    SMA 200$19.73
    EMA 10$21.89
    EMA 20$21.46
    EMA 50$19.86
    EMA 200$18.91

    MACD

    Line: 0.81Signal: 1.13Hist: -0.32

    ADX

    ADX: 26.7+DI: 23.8-DI: 21.6

    Aroon & PSAR

    Aroon Up68.0
    Aroon DownN/A
    PSAR$24.66

    Bollinger Bands

    Upper Band$24.68
    Lower Band$19.41
    %B Position2391%(Upper)
    Band Width0.49

    RSI (14-Day)

    Neutral
    57.9

    Momentum Oscillators

    Stoch %K18.3
    Stoch %D28.4
    Williams %R-65.9
    ROC (10d)-1.1%
    Momentum-0.24
    CCI (20d)-20.7
    MFI (14d)37.6

    Volatility Measures

    ATR (14d)$1.18(5.3%)
    StdDev (20d)1.32
    Hist Vol80.0%(High)

    Volume Flow

    VWAP$21.62
    OBV-4.5M
    AD Line-13.3M
    CMF (20d)0.146

    Volume Metrics

    Avg Vol (20d)2.0M
    Vol Ratio0.8x
    VWMA (20d)$21.83

    Pivot Points

    R3$22.28
    R2$22.02
    R1$21.73
    Pivot Point$21.47
    S1$21.18
    S2$20.92
    S3$20.63

    Advanced Oscillators

    TSI20.80
    Ultimate Osc48.3
    KST267.91

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$254.56M$247.22M$290.38M$249.25M$240.68M$234.42M$282.65M$243.97M$221.91M$191.67M$196.80M$185.62M
    Cost of Revenue$109.78M$110.43M$122.92M$114.96M$114.82M$116.02M$125.19M$119.32M$109.12M$97.00M$103.50M$95.87M
    Gross Profit$144.78M$136.79M$167.46M$134.29M$125.86M$118.41M$157.46M$124.65M$112.79M$94.67M$93.30M$89.75M
    Operating Expenses$158.57M$154.22M$159.17M$157.16M$177.66M$239.28M$158.04M$150.75M$143.57M$136.35M$128.35M$121.30M
    R&D$46.93M$46.03M$46.07M$48.72M$48.12M$125.43M$52.20M$51.11M$49.33M$46.24M$42.60M$41.97M
    SG&A$111.64M$108.19M$113.10M$108.44M$109.60M$113.85M$105.84M$99.64M$94.24M$90.11M$85.75M$79.33M
    Operating Income$-13,792,000$-17,434,000$8.29M$-22,863,000$-51,810,000$-120,878,000$-582,000$-26,093,000$-30,774,000$-41,678,000$-35,060,000$-31,545,000
    Interest Income$-4,416,000$-239,000$-1,537,000$-215,000$-4,007,000$651,000$2.46M$5.34M$2.82M$5.31M$5.55M$5.66M
    Interest Expense$2.45M$2.20M$2.08M$2.06M$1.91M$1.86M$1.86M$1.86M$1.79M$3.17M$1.80M$4.84M
    Income Before Tax$-20,658,000$-19,877,000$4.68M$-25,143,000$-57,722,000$-122,089,000$16,000$-22,614,000$-29,743,000$-39,529,000$-31,310,000$-30,729,000
    Income Tax Expense$510,000$516,000$5.27M$-3,978,000$-5,322,000$8.47M$-739,000$637,000$1.07M$3.19M$-1,308,000$2.23M
    Net Income$-21,168,000$-20,393,000$-589,000$-21,165,000$-52,400,000$-130,556,000$755,000$-23,251,000$-30,814,000$-42,715,000$-30,002,000$-32,961,000
    EBITDA$-9,588,000$-13,101,000$11.49M$-18,229,000$-47,610,000$-117,210,000$2.44M$-22,323,000$-25,449,000$-37,419,000$-30,126,000$-25,398,000
    EBIT$-13,792,000$-17,434,000$8.29M$-22,863,000$-51,810,000$-120,878,000$-582,000$-26,093,000$-30,774,000$-41,678,000$-35,060,000$-31,545,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about TNDM

    News

    Tandem Diabetes Care (TNDM) Loses 26.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

    Tandem Diabetes Care (TNDM) has experienced a 26.5% decline in its stock price over the past four weeks, but indicators suggest a potential trend reversal. The stock is technically in oversold territory according to the Relative Strength Index (RSI), and Wall Street analysts have raised earnings estimates for the company, further supporting the possibility of a rebound. TNDM also holds a Zacks Rank #2 (Buy), indicating strong potential for near-term turnaround.

    qz.com•8/26/26•
    Somewhat-Bullish

    William Blair initiates Tandem Diabetes stock with outperform rating

    William Blair initiated coverage on Tandem Diabetes Care (NASDAQ:TNDM) with an outperform rating, citing the company's strong pipeline, including the upcoming Mobi tubeless pump, and shifting selling model. Despite being unprofitable, the stock is considered undervalued by InvestingPro, and the company recently reported improved Q2 2026 financials with increased sales and gross margins. Oppenheimer also reiterated an Outperform rating, highlighting growth from pharmacy-channel sales and new products.

    Investing.com•8/21/26•
    Bullish

    TNDM Initiated Coverage On by William Blair -- Rating Set to Outperform

    William Blair initiated coverage on Tandem Diabetes Care (TNDM) with an 'Outperform' rating. The stock is considered 7.1% undervalued according to GF Value™, despite the company currently being unprofitable. Tandem Diabetes Care's GF Score™ is 71/100, reflecting strong growth and momentum but weaknesses in financial strength and profitability, warranting careful consideration from investors.

    GuruFocus•8/21/26•
    Bullish

    How Tandem’s Q2 Loss and Pharmacy Pivot Will Impact Tandem Diabetes Care (TNDM) Investors

    Tandem Diabetes Care (TNDM) reported a Q2 2026 net loss of US$21.17 million despite sales of US$254.56 million, while reaffirming full-year sales guidance of US$1.07 billion to US$1.09 billion. The company is pivoting towards pharmacy-based pump distribution and new insulin delivery technologies, a strategic shift that could impact its revenue generation and long-term earnings profile. Investors are advised to consider the potential of this pharmacy expansion against competitive risks and shifting reimbursement terms.

    Simply Wall Street•8/19/26•
    Somewhat-Bullish

    Tandem Diabetes (TNDM) CFO vests RSUs as shares withheld for tax

    Tandem Diabetes Care Inc. (TNDM) CFO Leigh Vosseller vested two blocks of Restricted Stock Units (RSUs) on August 15, 2026, acquiring 1,496 and 2,624 shares of common stock. To satisfy tax withholding obligations, the company withheld 537 and 942 shares at $22.72 per share, with no shares being sold. Following these transactions, Vosseller indirectly holds 25,580 shares in the Leigh A. Vosseller Trust.

    Stock Titan•8/19/26•
    Neutral

    Frequently Asked Questions About TNDM

    Does TNDM pay dividends?
    Tandem Diabetes Care Inc (TNDM) does not currently pay a regular dividend.
    What is TNDM's market cap?
    Tandem Diabetes Care Inc (TNDM) has a market capitalization of $1.49B with a current stock price of $22.01.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In